Gefitinib Tablets are a targeted therapy medication used primarily in the treatment of non-small cell lung cancer (NSCLC). As an epidermal growth factor receptor (EGFR) inhibitor, Gefitinib works by blocking the EGFR on the surface of cancer cells, thereby preventing the activation of key signaling pathways that promote cancer cell growth and survival. This selective action helps reduce tumor growth while minimizing damage to surrounding healthy tissues. Gefitinib is commonly prescribed for patients with advanced or metastatic NSCLC that harbor specific EGFR mutations, offering a more targeted and less toxic alternative to traditional chemotherapy.

Uses of Gefitinib Tablets
Gefitinib is most commonly used to treat metastatic or advanced non-small cell lung cancer (NSCLC) that tests positive for specific mutations in the EGFR gene. It is often prescribed as a first-line treatment for patients whose tumors are sensitive to EGFR inhibitors. By targeting the EGFR mutation, Gefitinib can significantly reduce tumor growth, improve progression-free survival, and in some cases, improve overall survival. Additionally, Gefitinib may be used in patients who have previously received chemotherapy or other treatments but have not responded well, providing another option for controlling cancer progression.

Side Effects of Gefitinib Tablets
Common side effects of Gefitinib include gastrointestinal issues such as diarrhea, nausea, and loss of appetite, as well as skin-related reactions like acne, rash, or dry skin. Many patients may also experience mild eye irritation or dryness, which should be monitored. More serious side effects can occur, including interstitial lung disease (ILD), which can cause severe lung inflammation, liver toxicity, and pulmonary problems. In rare cases, Gefitinib can cause severe allergic reactions, such as swelling of the face or throat, and require immediate medical attention. Regular monitoring of liver function, lung health, and skin condition is important throughout treatment.

Drug and Food Interactions
Gefitinib is usually taken on an empty stomach to enhance absorption. It may interact with medications that affect stomach acid, such as proton pump inhibitors (PPIs) or H2-receptor antagonists, as these can reduce the drug’s effectiveness. Additionally, drugs that influence the liver enzyme cytochrome P450, such as certain antibiotics, antifungals, or anti-seizure medications, may alter the metabolism of Gefitinib and lead to potential drug interactions. Patients should avoid grapefruit and grapefruit juice during treatment, as they can interfere with the metabolism of Gefitinib and potentially increase the risk of side effects. Always inform your healthcare provider of any other medications, supplements, or herbal products being taken to ensure safe and effective treatment.

Warnings and Precautions
Gefitinib should only be used under the supervision of a healthcare provider familiar with cancer treatment, particularly in patients with non-small cell lung cancer (NSCLC) harboring the EGFR mutation. Genetic testing for EGFR mutations is recommended before starting treatment to ensure that the medication will be effective. Monitoring for adverse effects such as interstitial lung disease, liver problems, and skin reactions is essential. Patients with a history of lung disease or liver impairment should be monitored closely, as they are at a higher risk for severe complications. Gefitinib is not recommended for use during pregnancy or breastfeeding, as it may harm the fetus or infant. Effective contraception should be used during treatment. Regular blood tests, including liver function tests and eye examinations, are advised to monitor the patient’s response to the medication and detect potential side effects early.

Conclusion
Gefitinib Tablets represent a significant advancement in the treatment of metastatic or advanced non-small cell lung cancer, particularly for patients with specific EGFR mutations. By specifically targeting cancer cells that rely on EGFR signaling for growth, Gefitinib provides a more focused and less toxic alternative to traditional chemotherapy. While side effects are possible, including skin reactions, gastrointestinal issues, and lung complications, careful monitoring and appropriate management allow many patients to benefit from this targeted therapy. Gefitinib remains an important option in the treatment of lung cancer, offering hope for improved survival and quality of life in patients with advanced-stage disease.